Abstract
Background: Epilepsy is a neurological disorder characterized by a decreased level of vitamins and endogenous antioxidants and an enhanced level of oxidative stress.
Objective: We designed this study to define the effects of combining melatonin, vitamin D3 (Vit D3), and agmatine on seizures caused by pentylenetetrazole (PTZ) in male NMRI mice. Methods: The experimental groups were as follows: the first group was administered normal saline (0.5 ml, i.p.) on the last day of the trial, and the second group was administered intraperitoneal PTZ (60 mg/kg) on that day. Pre-treatment with diazepam (4 mg/kg), vitamin D3 (6000 IU/kg, p.o.), agmatine (40 mg/kg, p.o.), and melatonin (20 mg/kg, p.o) was given to the next four groups before injecting PTZ (60 mg/kg, i.p.). The last group received a compound therapy of vitamin D3, melatonin, and agmatine before PTZ injection. Afterward, the latency, duration, and oxidative stress indications were evaluated in the brains of mice. Results: Treatments enhanced the latency of seizure and reduced seizure duration in comparison with the PTZ group; the compound group increased seizure latency more than Vit D3, agmatine, and melatonin groups and decreased the duration more than pre-treatment with Vit D3. We observed enhancement in superoxide dismutase (SOD) and catalase (CAT) activity in the treatment groups, while in the combination group, elevating CAT activity was comparable with Vit D3 and agmatine groups. The malondialdehyde level decreased in diazepam, agmatine, melatonin, and combination groups. Conclusion: The compound treatment was more efficient than each one alone in improving PTZinduced seizure, which may result from suppressing oxidative stress.Current Drug Therapy
Title:A Study on the Anticonvulsant Activity of the Simultaneous Administration of Melatonin, Agmatine, and Vitamin D3 on Pentylenetetrazole-Induced Seizures in Mice
Volume: 19
Author(s): Ali Jamshidi Naeini, Saeed Mehrzadi, Fahime Azimirad and Azam Hosseinzadeh*
Affiliation:
- Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
Abstract: Background: Epilepsy is a neurological disorder characterized by a decreased level of vitamins and endogenous antioxidants and an enhanced level of oxidative stress.
Objective: We designed this study to define the effects of combining melatonin, vitamin D3 (Vit D3), and agmatine on seizures caused by pentylenetetrazole (PTZ) in male NMRI mice. Methods: The experimental groups were as follows: the first group was administered normal saline (0.5 ml, i.p.) on the last day of the trial, and the second group was administered intraperitoneal PTZ (60 mg/kg) on that day. Pre-treatment with diazepam (4 mg/kg), vitamin D3 (6000 IU/kg, p.o.), agmatine (40 mg/kg, p.o.), and melatonin (20 mg/kg, p.o) was given to the next four groups before injecting PTZ (60 mg/kg, i.p.). The last group received a compound therapy of vitamin D3, melatonin, and agmatine before PTZ injection. Afterward, the latency, duration, and oxidative stress indications were evaluated in the brains of mice. Results: Treatments enhanced the latency of seizure and reduced seizure duration in comparison with the PTZ group; the compound group increased seizure latency more than Vit D3, agmatine, and melatonin groups and decreased the duration more than pre-treatment with Vit D3. We observed enhancement in superoxide dismutase (SOD) and catalase (CAT) activity in the treatment groups, while in the combination group, elevating CAT activity was comparable with Vit D3 and agmatine groups. The malondialdehyde level decreased in diazepam, agmatine, melatonin, and combination groups. Conclusion: The compound treatment was more efficient than each one alone in improving PTZinduced seizure, which may result from suppressing oxidative stress.Export Options
About this article
Cite this article as:
Naeini Jamshidi Ali, Mehrzadi Saeed, Azimirad Fahime and Hosseinzadeh Azam*, A Study on the Anticonvulsant Activity of the Simultaneous Administration of Melatonin, Agmatine, and Vitamin D3 on Pentylenetetrazole-Induced Seizures in Mice, Current Drug Therapy 2024; 19 () . https://dx.doi.org/10.2174/0115748855311635240723054816
DOI https://dx.doi.org/10.2174/0115748855311635240723054816 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers